Medications

Axicabtagene ciloleucel slows large B-cell lymphoma

(HealthDay)—For patients with refractory or relapsed large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) leads to improvements in event-free survival and response compared with standard care, according to a study published ...

Oncology & Cancer

Thanks to clinical trials, big leaps made in lymphoma treatment

Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...

page 34 from 40